공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트
SALE

세계의 항진균제 시장 : 약제 클래스별, 적응증별, 감염증 종류별, 투여 경로별, 최종사용자별, 유통 경로별, 지역별 - 경쟁, 예측 및 기회(2026년)

Global Anti-Fungal Drugs Market, By Drug Class, By Indication, By Infection Type, By Route of Administration, By End User By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026

리서치사 TechSci Research
발행일 2021년 10월 상품 코드 1030946
페이지 정보 영문 114 Pages
가격
US $ 4,900 US $ 4,400 ₩ 5,250,000 Unprintable PDF and Excel (Single User License)
US $ 4,900 ₩ 5,847,000 Unprintable PDF and Excel (Single User License)
US $ 5,900 ₩ 7,041,000 PDF and Excel (Multi-User License)
US $ 8,900 ₩ 10,621,000 PDF and Excel (Custom Research License)

TechSci Research 보고서는 10% Customization 서비스가 포함되어 있습니다. 보고서에 포함돼 있지 않은 리서치 데이터와 시장 동향을 추가적으로 요청할 수 있습니다. 자세한 사항은 문의하여 주시기 바랍니다.



세계의 항진균제 시장 : 약제 클래스별, 적응증별, 감염증 종류별, 투여 경로별, 최종사용자별, 유통 경로별, 지역별 - 경쟁, 예측 및 기회(2026년) Global Anti-Fungal Drugs Market, By Drug Class, By Indication, By Infection Type, By Route of Administration, By End User By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026
발행일 : 2021년 10월 페이지 정보 : 영문 114 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 항진균제 시장 규모는 2026년에는 284억 8,469만 달러에 달할 것으로 보이며, 예측기간 중 10.39%의 CAGR로 성장할 것으로 예측됩니다.

예측기간 중 시장 성장의 주요 요인은 진균 감염증 증가로 생각됩니다. 진균 감염증이 인체에 미치는 악영향에 대한 환자 의식 향상이 세계에서 항진균제 수요를 크게 촉진하고 있습니다. 항진균제를 개발하기 위한 연구개발 활동을 촉진하기 위한 정부 자금이나 투자가 증가하고 있는 점도 시장 성장을 지지하고 있습니다.

항진균제 사용량 증가와 시판되고 있는 항진균제 수 증가가 시장 수요를 지지할 것으로 예상됩니다. 또한 손발톱에 감염하는 진균증인 '조진균증' 증가도 항진균제 수요를 높이는 큰 요인으로 생각됩니다.

세계의 항진균제(Anti-Fungal Drugs) 시장에 대해 조사했으며, 고객의 소리, 시장 전망, 시장 역학, 경쟁 상황 등의 정보를 제공합니다.

목차

제1장 제품 개요

제2장 조사 방법

제3장 COVID-19가 세계의 항진균제 시장에 미치는 영향

제4장 주요 요약

제5장 고객의 소리

  • 브랜드 인지도
  • 진균성 질환 유병률에 기여하는 요인
  • 일반적으로 관찰되는 진균증

제6장 세계의 항진균제 시장 전망

  • 시장 규모와 예측
    • 가치별
  • 시장 점유율과 예측
    • 약제 클래스별(아졸, 에키노칸딘, 폴리엔, 알릴아민, 기타)
    • 적응증별(칸디다증, 아스페르길루스증, 털곰팡이증, 피부사상균증, 기타)
    • 감염증 종류별(표재성 진균 감염, 전신성 진균 감염)
    • 투여 경로별(국소, 경구, 비경구, 기타)
    • 최종사용자별(홈케어, 병원, 클리닉, 기타)
    • 유통 경로별(소매 약국, 병원 약국, 온라인 약국)
    • 지역별
    • 기업별(2020년)
  • 제품 시장 맵

제7장 북미의 항진균제 시장 전망

  • 시장 규모와 예측
    • 가치별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 적응증별
    • 감염증 종류별
    • 투여 경로별
    • 최종사용자별
    • 유통 경로별
    • 국가별
  • 북미 : 국가별 분석
    • 미국의 항진균제 시장 전망
    • 멕시코의 항진균제 시장 전망
    • 캐나다의 항진균제 시장 전망

제8장 유럽의 항진균제 시장 전망

  • 시장 규모와 예측
    • 가치별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 적응증별
    • 감염증 종류별
    • 투여 경로별
    • 최종사용자별
    • 유통 경로별
    • 국가별
  • 유럽 : 국가별 분석
    • 러시아의 항진균제 시장 전망
    • 독일의 항진균제 시장 전망
    • 프랑스의 항진균제 시장 전망
    • 영국의 항진균제 시장 전망
    • 이탈리아의 항진균제 시장 전망
    • 스페인의 항진균제 시장 전망
    • 폴란드의 항진균제 시장 전망

제9장 아시아태평양의 항진균제 시장 전망

  • 시장 규모와 예측
    • 가치별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 적응증별
    • 감염증 종류별
    • 투여 경로별
    • 최종사용자별
    • 유통 경로별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 인도의 항진균제 시장 전망
    • 중국의 항진균제 시장 전망
    • 인도네시아의 항진균제 시장 전망
    • 일본의 항진균제 시장 전망
    • 한국의 항진균제 시장 전망
    • 말레이시아의 항진균제 시장 전망
    • 호주의 항진균제 시장 전망

제10장 남미의 항진균제 시장 전망

  • 시장 규모와 예측
    • 가치별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 적응증별
    • 감염증 종류별
    • 투여 경로별
    • 최종사용자별
    • 유통 경로별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질의 항진균제 시장 전망
    • 콜롬비아의 항진균제 시장 전망
    • 아르헨티나의 항진균제 시장 전망

제11장 중동 및 아프리카의 항진균제 시장 전망

  • 시장 규모와 예측
    • 가치별
  • 시장 점유율과 예측
    • 약제 클래스별
    • 적응증별
    • 감염증 종류별
    • 투여 경로별
    • 최종사용자별
    • 유통 경로별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 나이지리아의 항진균제 시장 전망
    • 터키의 항진균제 시장 전망
    • 남아프리카공화국의 항진균제 시장 전망
    • 사우디아라비아의 항진균제 시장 전망
    • 아랍에미리트의 항진균제 시장 전망

제12장 시장 역학

  • 성장 촉진요인
  • 과제

제13장 시장 동향과 전개

제14장 경쟁 상황

  • 경쟁 전망
  • 기업 개요
    • Astellas Pharma Inc.
    • GlaxoSmithKline Plc
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd.
    • Gilead Sciences Inc.
    • Janssen Pharmaceuticals Inc.(Johnson & Johnson)
    • Pfizer Inc.
    • Sanofi S.A.
    • Merck & Co., Inc.
    • Glenmark Pharmaceuticals Ltd.
    • Sun Pharmaceuticals Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.(Mylan Laboratories Inc.)
    • Cipla Ltd.
    • Zydus Cadila Ltd.
    • Lupin Ltd.
    • Torrent Pharmaceuticals Ltd
    • Abbott Laboratories Inc
    • Novartis AG
    • Galderma SA

제15장 전략적 추천사항

제16장 TechSci Research 소개와 면책사항

KSM 21.10.14

List of Figures

  • Figure 1: Global Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 2: Global Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 3: Global Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 4: Global Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 5: Global Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 6: Global Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 7: Global Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 8: Global Anti-Fungal Drugs Market Share, By Region, By Value, 2016-2026
  • Figure 9: Global Anti-Fungal Drugs Market Share, By Company, By Value, 2020
  • Figure 10: Global Anti-Fungal Drugs Product Market Map, By Value, 2016-2026F
  • Figure 11: North America Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 12: North America Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 13: North America Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 14: North America Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 15: North America Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 16: North America Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 17: North America Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 18: North America Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 19: United States Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 20: United States Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 21: United States Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 22: United States Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 23: United States Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 24: United States Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 25: United States Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 26: Mexico Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 27: Mexico Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 28: Mexico Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 29: Mexico Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 30: Mexico Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 31: Mexico Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 32: Mexico Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 33: Canada Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 34: Canada Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 35: Canada Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 36: Canada Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 37: Canada Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 38: Canada Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 39: Canada Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 40: Europe Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 41: Europe Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 42: Europe Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 43: Europe Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 44: Europe Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 45: Europe Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 46: Europe Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 47: Europe Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 48: Russia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 49: Russia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 50: Russia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 51: Russia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 52: Russia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 53: Russia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 54: Russia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 55: Germany Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 56: Germany Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 57: Germany Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 58: Germany Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 59: Germany Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 60: Germany Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 61: Germany Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 62: France Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 63: France Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 64: France Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 65: France Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 66: France Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 67: France Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 68: France Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 69: United Kingdom Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 70: United Kingdom Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 71: United Kingdom Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 72: United Kingdom Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 73: United Kingdom Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 74: United Kingdom Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 75: United Kingdom Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 76: Italy Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 77: Italy Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 78: Italy Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 79: Italy Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 80: Italy Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 81: Italy Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 82: Italy Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 83: Spain Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 84: Spain Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 85: Spain Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 86: Spain Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 87: Spain Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 88: Spain Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 89: Spain Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 90: Poland Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 91: Poland Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 92: Poland Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 93: Poland Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 94: Poland Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 95: Poland Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 96: Poland Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 97: Asia-Pacific Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 98: Asia-Pacific Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 99: Asia-Pacific Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 100: Asia-Pacific Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 101: Asia-Pacific Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 102: Asia-Pacific Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 103: Asia-Pacific Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 104: Asia-Pacific Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 105: India Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 106: India Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 107: India Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 108: India Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 109: India Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 110: India Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 111: India Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 112: China Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 113: China Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 114: China Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 115: China Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 116: China Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 117: China Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 118: China Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 119: Indonesia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 120: Indonesia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 121: Indonesia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 122: Indonesia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 123: Indonesia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 124: Indonesia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 125: Indonesia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 126: Japan Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 127: Japan Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 128: Japan Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 129: Japan Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 130: Japan Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 131: Japan Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 132: Japan Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 133: South Korea Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 134: South Korea Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 135: South Korea Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 136: South Korea Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 137: South Korea Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 138: South Korea Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 139: South Korea Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 140: Malaysia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 141: Malaysia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 142: Malaysia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 143: Malaysia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 144: Malaysia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 145: Malaysia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 146: Malaysia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 147: Australia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 148: Australia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 149: Australia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 150: Australia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 151: Australia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 152: Australia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 153: Australia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 154: South America Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 155: South America Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 156: South America Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 157: South America Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 158: South America Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 159: South America Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 160: South America Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 161: South America Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 162: Brazil Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 163: Brazil Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 164: Brazil Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 165: Brazil Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 166: Brazil Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 167: Brazil Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 168: Brazil Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 169: Colombia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 170: Colombia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 171: Colombia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 172: Colombia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 173: Colombia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 174: Colombia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 175: Colombia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 176: Argentina Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 177: Argentina Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 178: Argentina Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 179: Argentina Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 180: Argentina Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 181: Argentina Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 182: Argentina Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 183: Middle East and Africa Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 184: Middle East and Africa Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 185: Middle East and Africa Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 186: Middle East and Africa Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 187: Middle East and Africa Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 188: Middle East and Africa Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 189: Middle East and Africa Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 190: Middle East and Africa Anti-Fungal Drugs Market Share, By Country, By Value, 2016-2026F
  • Figure 191: Nigeria Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 192: Nigeria Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 193: Nigeria Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 194: Nigeria Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 195: Nigeria Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 196: Nigeria Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 197: Nigeria Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 198: Turkey Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 199: Turkey Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 200: Turkey Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 201: Turkey Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 202: Turkey Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 203: Turkey Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 204: Turkey Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 205: South Africa Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 206: South Africa Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 207: South Africa Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 208: South Africa Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 209: South Africa Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 210: South Africa Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 211: South Africa Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 212: Saudi Arabia Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 213: Saudi Arabia Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 214: Saudi Arabia Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 215: Saudi Arabia Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 216: Saudi Arabia Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 217: Saudi Arabia Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 218: Saudi Arabia Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F
  • Figure 219: UAE Anti-Fungal Drugs Market Size, By Value (USD Million), 2016-2026F
  • Figure 220: UAE Anti-Fungal Drugs Market Share, By Drug Class, By Value, 2016-2026F
  • Figure 221: UAE Anti-Fungal Drugs Market Share, By Indication, By Value, 2016-2026F
  • Figure 222: UAE Anti-Fungal Drugs Market Share, By Infection Type, By Value, 2016-2026F
  • Figure 223: UAE Anti-Fungal Drugs Market Share, By Route of Administration, By Value, 2016-2026F
  • Figure 224: UAE Anti-Fungal Drugs Market Share, By End User, By Value, 2016-2026F
  • Figure 225: UAE Anti-Fungal Drugs Market Share, By Distribution Channel, By Value, 2016-2026F

Global anti-fungal drugs market is expected to reach USD28484.69 million by 2026, growing at CAGR of 10.39% over the forecast period. Fungal infections can lead to diseases including fungal pneumonia, candidiasis, mucormycosis, among others and these fungal infections require the dosage of anti-fungal drugs to ensure effective treatment. The increasing prevalence of fungal infections is considered the primary driver for the market growth in the forecast period. The rise in awareness levels among patients regarding the adverse effect of fungal infection on the human body is significantly accelerating the demand for anti-fungal drugs around the world. An increase in government funds and investments to promote research and development activities to formulate anti-fungal drugs is fueling the market growth. An increase in the use of anti-fungal drugs coupled with the rising number of anti-fungal drugs available over-the-counter is expected to boost the market demand. With the surge in popularity of over-the-counter drugs such as ketoconazole, miconazole, econazole, amorolfine, several patients are preferring over-the-counter drugs. The rise in onychomycosis cases, which is a fungal infection affecting fingers and toenails is also considered a major driver responsible for the high demand for anti-fungal drugs.

The global anti-fungal drugs market is segmented into drug class, indication, infection type, route of administration, end-user, distribution channel, regional distribution, and company. Based on drug class, market is further divided into azoles, echinocandins, polyenes, allylamines and others. The azoles segment is expected to dominate the anti-fungal drugs market in the forecast period owing to their use in treatment of almost all the indications. Based on indication, the market is segmented into candidiasis, aspergillosis, dermatophytosis, mucormycosis, and others. The candidiasis segment is expected to dominate the market owing to high cases globally associated with the fungal species.

Based on regional analysis, North America is expected to dominate the anti-fungal drugs market for the next five years owing to the presence of major market players in the region. The high prevalence of fungal infections in the region is another crucial factor aiding the market growth. Well-developed healthcare infrastructure and favorable government healthcare policies are the other significant factors bolstering the market growth.

The major players operating in the global anti-fungal drugs market are Astellas Pharma Inc., GlaxoSmithKline Plc, Bayer AG, Dr. Reddy's Laboratories Ltd., Gilead Sciences Inc., Janssen Pharmaceuticals Inc. (Johnson & Johnson), Pfizer Inc., Sanofi S.A., Merck & Co., Inc., Glenmark Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc. (Mylan Laboratories Inc.), Cipla Ltd., Zydus Cadila Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd, Abbott Laboratories Inc., Novartis AG, Galderma SA among others. Major companies are developing advanced technologies and launching new anti-fungal drugs to stay competitive in the market. Other competitive strategies include mergers & acquisitions and new product developments.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022-2026

Objective of the Study:

  • To analyze the historical growth in the market size of global anti-fungal drugs market from 2016 to 2020.
  • To estimate and forecast the market size of global anti-fungal drugs market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global anti-fungal drugs market based on drug class, indication, infection type, route of administration, end user, distribution channel, regional distribution, and company.
  • To identify dominant region or segment in the global anti-fungal drugs market.
  • To identify drivers and challenges for global anti-fungal drugs market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global anti-fungal drugs market.
  • To identify and analyze the profile of leading players operating in global anti-fungal drugs market.
  • To identify key sustainable strategies adopted by market players in global anti-fungal drugs market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers who could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global anti-fungal drugs market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of various segments for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Anti-fungal drug manufacturing companies
  • Market research and consulting firms
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to anti-fungal drugs market

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers and partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global anti-fungal drugs market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Anti-Fungal Drugs Market, By Drug Class:

Azoles

Echinocandins

Polyenes

Allylamines

Others

  • Global Anti-Fungal Drugs Market, By Indication:

Candidiasis

Aspergillosis

Mucormycosis

Dermatophytosis

Others

  • Global Anti-Fungal Drugs Market, By Infection Type:

Superficial Fungal Infection

Systemic Fungal Infection

  • Global Anti-Fungal Drugs Market, By Route of Administration:

Topical

Oral

Parenteral

Others

  • Global Anti-Fungal Drugs Market, By End-User:

Homecare

Hospitals

Clinics

Others

  • Global Anti-Fungal Drugs Market, By Distribution Channel:

Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

  • Global Anti-Fungal Drugs Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • Russia
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Poland

Asia-Pacific

  • India
  • China
  • Indonesia
  • Japan
  • South Korea
  • Malaysia
  • Australia

South America

  • Brazil
  • Colombia
  • Argentina

Middle East & Africa

  • Nigeria
  • Turkey
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global anti-fungal drugs market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Anti-Fungal Drugs Market

4. Executive Summary

5. Voice of Customer

  • 5.1. Brand Awareness
  • 5.2. Factors Contributing to the Prevalence of Fungal Diseases
  • 5.3. Commonly Observed Fungal Diseases

6. Global Anti-Fungal Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class (Azoles, Echinocandins, Polyenes, Allylamines, Others)
    • 6.2.2. By Indication (Candidiasis, Aspergillosis, Mucormycosis, Dermatophytosis, Others)
    • 6.2.3. By Infection Type (Superficial Fungal Infection v/s Systemic Fungal Infection)
    • 6.2.4. By Route of Administration (Topical, Oral, Parenteral, Others)
    • 6.2.5. By End User (Homecare, Hospitals, Clinics, Others)
    • 6.2.6. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy)
    • 6.2.7. By Region
    • 6.2.8. By Company (2020)
  • 6.3. Product Market Map

7. North America Anti-Fungal Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Indication
    • 7.2.3. By Infection Type
    • 7.2.4. By Route of Administration
    • 7.2.5. By End User
    • 7.2.6. By Distribution Channel
    • 7.2.7. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Anti-Fungal Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Infection Type
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By End User
        • 7.3.1.2.6. By Distribution Channel
    • 7.3.2. Mexico Anti-Fungal Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Infection Type
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By End User
        • 7.3.2.2.6. By Distribution Channel
    • 7.3.3. Canada Anti-Fungal Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Infection Type
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By End User
        • 7.3.3.2.6. By Distribution Channel

8. Europe Anti-Fungal Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Indication
    • 8.2.3. By Infection Type
    • 8.2.4. By Route of Administration
    • 8.2.5. By End User
    • 8.2.6. By Distribution Channel
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. Russia Anti-Fungal Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Infection Type
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By End User
        • 8.3.1.2.6. By Distribution Channel
    • 8.3.2. Germany Anti-Fungal Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Infection Type
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By End User
        • 8.3.2.2.6. By Distribution Channel
    • 8.3.3. France Anti-Fungal Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Infection Type
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By End User
        • 8.3.3.2.6. By Distribution Channel
    • 8.3.4. United Kingdom Anti-Fungal Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Infection Type
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By End User
        • 8.3.4.2.6. By Distribution Channel
    • 8.3.5. Italy Anti-Fungal Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Infection Type
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By End User
        • 8.3.5.2.6. By Distribution Channel
    • 8.3.6. Spain Anti-Fungal Drugs Market Outlook
      • 8.3.6.1. Market Size & Forecast
        • 8.3.6.1.1. By Value
      • 8.3.6.2. Market Share & Forecast
        • 8.3.6.2.1. By Drug Class
        • 8.3.6.2.2. By Indication
        • 8.3.6.2.3. By Infection Type
        • 8.3.6.2.4. By Route of Administration
        • 8.3.6.2.5. By End User
        • 8.3.6.2.6. By Distribution Channel
    • 8.3.7. Poland Anti-Fungal Drugs Market Outlook
      • 8.3.7.1. Market Size & Forecast
        • 8.3.7.1.1. By Value
      • 8.3.7.2. Market Share & Forecast
        • 8.3.7.2.1. By Drug Class
        • 8.3.7.2.2. By Indication
        • 8.3.7.2.3. By Infection Type
        • 8.3.7.2.4. By Route of Administration
        • 8.3.7.2.5. By End User
        • 8.3.7.2.6. By Distribution Channel

9. Asia-Pacific Anti-Fungal Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Indication
    • 9.2.3. By Infection Type
    • 9.2.4. By Route of Administration
    • 9.2.5. By End User
    • 9.2.6. By Distribution Channel
    • 9.2.7. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. India Anti-Fungal Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Infection Type
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By End User
        • 9.3.1.2.6. By Distribution Channel
    • 9.3.2. China Anti-Fungal Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Infection Type
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By End User
        • 9.3.2.2.6. By Distribution Channel
    • 9.3.3. Indonesia Anti-Fungal Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Infection Type
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By End User
        • 9.3.3.2.6. By Distribution Channel
    • 9.3.4. Japan Anti-Fungal Drugs Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Class
        • 9.3.4.2.2. By Indication
        • 9.3.4.2.3. By Infection Type
        • 9.3.4.2.4. By Route of Administration
        • 9.3.4.2.5. By End User
        • 9.3.4.2.6. By Distribution Channel
    • 9.3.5. South Korea Anti-Fungal Drugs Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Drug Class
        • 9.3.5.2.2. By Indication
        • 9.3.5.2.3. By Infection Type
        • 9.3.5.2.4. By Route of Administration
        • 9.3.5.2.5. By End User
        • 9.3.5.2.6. By Distribution Channel
    • 9.3.6. Malaysia Anti-Fungal Drugs Market Outlook
      • 9.3.6.1. Market Size & Forecast
        • 9.3.6.1.1. By Value
      • 9.3.6.2. Market Share & Forecast
        • 9.3.6.2.1. By Drug Class
        • 9.3.6.2.2. By Indication
        • 9.3.6.2.3. By Infection Type
        • 9.3.6.2.4. By Route of Administration
        • 9.3.6.2.5. By End User
        • 9.3.6.2.6. By Distribution Channel
    • 9.3.7. Australia Anti-Fungal Drugs Market Outlook
      • 9.3.7.1. Market Size & Forecast
        • 9.3.7.1.1. By Value
      • 9.3.7.2. Market Share & Forecast
        • 9.3.7.2.1. By Drug Class
        • 9.3.7.2.2. By Indication
        • 9.3.7.2.3. By Infection Type
        • 9.3.7.2.4. By Route of Administration
        • 9.3.7.2.5. By End User
        • 9.3.7.2.6. By Distribution Channel

10. South America Anti-Fungal Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Indication
    • 10.2.3. By Infection Type
    • 10.2.4. By Route of Administration
    • 10.2.5. By End User
    • 10.2.6. By Distribution Channel
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Anti-Fungal Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Infection Type
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By End User
        • 10.3.1.2.6. By Distribution Channel
    • 10.3.2. Colombia Anti-Fungal Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Infection Type
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By End User
        • 10.3.2.2.6. By Distribution Channel
    • 10.3.3. Argentina Anti-Fungal Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Infection Type
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By End User
        • 10.3.3.2.6. By Distribution Channel

11. Middle East and Africa Anti-Fungal Drugs Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Drug Class
    • 11.2.2. By Indication
    • 11.2.3. By Infection Type
    • 11.2.4. By Route of Administration
    • 11.2.5. By End User
    • 11.2.6. By Distribution Channel
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. Nigeria Anti-Fungal Drugs Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Drug Class
        • 11.3.1.2.2. By Indication
        • 11.3.1.2.3. By Infection Type
        • 11.3.1.2.4. By Route of Administration
        • 11.3.1.2.5. By End User
        • 11.3.1.2.6. By Distribution Channel
    • 11.3.2. Turkey Anti-Fungal Drugs Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Drug Class
        • 11.3.2.2.2. By Indication
        • 11.3.2.2.3. By Infection Type
        • 11.3.2.2.4. By Route of Administration
        • 11.3.2.2.5. By End User
        • 11.3.2.2.6. By Distribution Channel
    • 11.3.3. South Africa Anti-Fungal Drugs Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Drug Class
        • 11.3.3.2.2. By Indication
        • 11.3.3.2.3. By Infection Type
        • 11.3.3.2.4. By Route of Administration
        • 11.3.3.2.5. By End User
        • 11.3.3.2.6. By Distribution Channel
    • 11.3.4. Saudi Arabia Anti-Fungal Drugs Market Outlook
      • 11.3.4.1. Market Size & Forecast
        • 11.3.4.1.1. By Value
      • 11.3.4.2. Market Share & Forecast
        • 11.3.4.2.1. By Drug Class
        • 11.3.4.2.2. By Indication
        • 11.3.4.2.3. By Infection Type
        • 11.3.4.2.4. By Route of Administration
        • 11.3.4.2.5. By End User
        • 11.3.4.2.6. By Distribution Channel
    • 11.3.5. UAE Anti-Fungal Drugs Market Outlook
      • 11.3.5.1. Market Size & Forecast
        • 11.3.5.1.1. By Value
      • 11.3.5.2. Market Share & Forecast
        • 11.3.5.2.1. By Drug Class
        • 11.3.5.2.2. By Indication
        • 11.3.5.2.3. By Infection Type
        • 11.3.5.2.4. By Route of Administration
        • 11.3.5.2.5. By End User
        • 11.3.5.2.6. By Distribution Channel

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled
    • 14.2.1. Astellas Pharma Inc.
    • 14.2.2. GlaxoSmithKline Plc
    • 14.2.3. Bayer AG
    • 14.2.4. Dr. Reddy's Laboratories Ltd.
    • 14.2.5. Gilead Sciences Inc.
    • 14.2.6. Janssen Pharmaceuticals Inc. (Johnson & Johnson)
    • 14.2.7. Pfizer Inc.
    • 14.2.8. Sanofi S.A.
    • 14.2.9. Merck & Co., Inc.
    • 14.2.10. Glenmark Pharmaceuticals Ltd.
    • 14.2.11. Sun Pharmaceuticals Industries Ltd.
    • 14.2.12. Teva Pharmaceutical Industries Ltd.
    • 14.2.13. Viatris Inc. (Mylan Laboratories Inc.)
    • 14.2.14. Cipla Ltd.
    • 14.2.15. Zydus Cadila Ltd.
    • 14.2.16. Lupin Ltd.
    • 14.2.17. Torrent Pharmaceuticals Ltd
    • 14.2.18. Abbott Laboratories Inc
    • 14.2.19. Novartis AG
    • 14.2.20. Galderma SA

15. Strategic Recommendations

16. About Us & Disclaimer

Back to Top
전화 문의
F A Q